At the U.S. District Court in East St. Louis, the fight over how thousands of paraquat cases should end is getting unusually heated. Lawyers for roughly 6,500 plaintiffs and for Syngenta are wrestling over a proposed master settlement that would resolve claims that the company’s herbicide caused Parkinson's disease. According to court filings and attorneys in the room, the framework on the table would require participating plaintiffs to drop their lawsuits and sign broad releases. Several plaintiffs’ lawyers say the proposed terms quietly raise the bar for proving causation and could leave many people with relatively modest checks in exchange for giving up their claims. For now, Chief Judge Nancy Rosenstengel has put bellwether trials on ice while negotiations continue and has warned she intends to police the settlement process closely.
As reported by St. Louis Magazine, those tensions spilled into the open when Denver plaintiffs’ attorney Aimee Wagstaff, a vocal critic of the deal, leaned over to a colleague in court and said, "It's a shitty settlement. Spread that far and wide in case I get gagged." According to the magazine, Rosenstengel accused Wagstaff of trying to "subvert" the settlement process and ordered her to come back and explain herself in person. Wagstaff and other critics argue the proposed deal appears to require evidence standards and medical thresholds that could screen out many workers who say paraquat left them sick.
Judge Demands an Explanation
An October 6, 2025 order from Chief Judge Nancy J. Rosenstengel warned lawyers against any efforts to "undermine" the multidistrict litigation settlement process and directed Wagstaff to appear in person to discuss a planned webinar, according to a U.S. District Court filing. The MDL docket also shows Rosenstengel has repeatedly extended stays on case-specific discovery to give settlement talks room to breathe. Because the judge is supervising the process, any master deal that emerges will need her approval before it can bind thousands of MDL claimants.
What the Deal Would Mean
Plaintiffs’ leadership and Syngenta say they have agreed on a broad settlement framework and that a payout schedule will be circulated so individual plaintiffs can decide whether to opt in or stay out, The New Lede reports. Syngenta has already told investors that it paid about $187.5 million into paraquat-related settlements in 2021, a detail highlighted in international coverage of the litigation by SwissInfo. Under the current draft, qualifying plaintiffs who join the program would be required to dismiss their lawsuits and sign a broad release, while the specific dollar amount each person receives would depend on how many people participate and how claims are ranked in a tiered system.
Why Some Lawyers Object
Some plaintiffs’ attorneys say the draft agreement effectively slams the door on many of their clients by insisting on strict proof of both a Parkinson’s diagnosis and paraquat exposure, a concern described by St. Louis Magazine. Outside legal commentary has suggested that average settlement values could land in the low six figures, roughly $100,000 to $150,000 in many cases, although amounts would vary by severity of injury and where a case is filed, according to analysis from Beasley Allen. That basic math gives some plaintiffs a strong incentive to roll the dice at trial and gives the defendants every reason to push for a broad, fast resolution.
Science and the Stakes
The health claims at the core of the litigation lean on decades of research that link pesticide exposure to Parkinson’s disease. The Parkinson's Foundation summarizes epidemiological studies tying paraquat and other pesticides to an increased risk of PD, while a recent peer-reviewed review in the scientific literature sets out toxicological mechanisms that show how paraquat can damage dopamine-producing neurons in lab models, as documented in PubMed Central. Those lines of scientific evidence are what plaintiffs point to when they try to prove causation in court.
Trials, Settlements and a Pattern
Veteran courtroom watchers note that cases that get close to trial often disappear quietly into last-minute settlements, and the paraquat litigation is following that playbook. In late January, Syngenta reached a confidential settlement in a Philadelphia bellwether case that had been set to be the first U.S. trial to test the allegations, The New Lede reports. Some plaintiffs’ lawyers worry that this pattern will keep key corporate documents and contested scientific testimony out of the public eye, limiting not only the pressure on Syngenta but also the broader debate over pesticide regulation and public health.
What Comes Next
Even while settlement talks continue, the MDL judge has kept a tight grip on the calendar. Orders extending stays and canceling status conferences remain posted as lawyers work through the details, according to the U.S. District Court. If a master settlement is formally rolled out, plaintiffs will see a payout grid and will be given a choice: opt in and take the settlement, or opt out and move ahead toward trial. For families and farmworkers who have been waiting years for answers, that decision boils down to whether they prefer a faster, likely smaller recovery or want to keep pushing for a jury to weigh the science and the company’s conduct.
Legal Implications
If the court blesses a master settlement, the legal finality will be significant. Plaintiffs who accept the program will generally be required to dismiss their lawsuits and sign broad releases that shut the door on future claims tied to the same paraquat exposure. That trade-off, a certain and quicker payment versus the risk and potential reward of a larger jury verdict, is exactly what is driving the split between some plaintiffs’ lawyers and the companies. The court’s hands-on oversight, combined with Syngenta’s prior disclosures about paraquat settlement funds, underscores just how weighty that choice will be for people living with Parkinson’s disease and for the families counting on them.
